Organization
Innovative Medicines Canada
- Meetings this Parliament
- 98
- With MPs
- 37
- Since Nov 2021
- 279
- Active registrations
- 1
Most recent reported meeting: Sep 18, 2026.
Lobbying by Innovative Medicines Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingWho they meet
Since the current Parliament opened.
MPs
- Maggie Chi Liberal 4
- Karim Bardeesy Liberal 3
- Marjorie Michel Liberal 3
- Tom Kmiec Conservative 3
- Helena Jaczek Liberal 2
- Mélanie Joly Liberal 2
- Burton Bailey Conservative 1
- Jagsharan Singh Mahal Conservative 1
- Kurt Holman Conservative 1
- Matt Strauss Conservative 1
- John Zerucelli Liberal 1
- Charles Sousa Liberal 1
Institutions
- House of Commons32
- Health Canada (HC)22
- Innovation, Science and Economic Development Canada (ISED)21
- Finance Canada (FIN)10
- Treasury Board Of Canada Secretariat (TBS)7
- Privy Council Office (PCO)7
- Intergovernmental Affairs Secretariat (IGA)7
- Global Affairs Canada (GAC)7
Registrations in effect
In-house (organization) In effect since Sep 11, 2026
Filed by Bettina Hamelin, President and CEO
Lobbyists
-
Patricia Best · Vice-President, Government and Stakeholder Relations
Former designated public office holder
Formerly Senior Special Advisor, Office of the Minister of Finance, Minister of Finance (2014–2015)
Formerly Director of Communications, Minister's Office - Natural Resources Canada, Minister of National Resources Canada (2011–2012)
-
Agata Stankiewicz · Senior Director, Government Relations, Ontario
Former public office holder
Formerly Trade Commissioner, Toronto Office, Global Affairs Canada (2018–2018)
Formerly Policy Analyst, Office of International Affairs for the Health Portfolio, Public Health Agency of Canada (2016–2018)
Formerly Policy Analyst, Social Determinants and Science Integration Directorate, Public Health Agency of Canada (2012–2016)
Formerly Epidemiologist, Centre for Chronic Disease Prevention, Public Health Agency of Canada (2010–2012)
-
Bettina Hamelin · President and CEO
Former public office holder
Formerly Vice President, Research Partnerships, Natural Sciences and Engineering Research Council of Canada, Council of Canada (2015–2017)
- Brendan Lounsbery · General Counsel & Vice President, Legal, Compliance & Regulatory
-
Charles Brown · Director, Government Affairs, West
Former public office holder
Formerly Labour Market Economic Analyst, Economic Services, Employment and Immigration Canada (1989–1992)
- Greg Hein · Vice President, Strategy, Systems Transformation & Research
-
Hugh Scott · Executive Director, Strategic Alliances
Former public office holder
Formerly Legislative Assistant to Albina Guarnieri, M.P. - Parliamentary Secretary to the Minister of Canadian Heritage, Parliament Hill Office, Canadian Heritage (1994–1998)
- Jennifer Buckley · Senior Director, Regulatory Affairs and Clinical Research Transformation
- Joe Farago · Executive Director, Market Access
- Kristian LeBlanc · Senior Director, Atlantic, Government Relations
-
Michael Dietrich · Vice President, Market Access Policy
Former public office holder
Formerly Jr. Research Analyst, Industrial Analysis, Industry Canada (2004–2004)
-
Sophie Normand · Director, Federal Government Relations
Former public office holder
Formerly Social Media Coordinator, Communications Directorate, Senate of Canada (2020–2021)
Formerly Social Media and Special Projects Coordinator, Office of the Speaker of the House of Commons, Parliament of Canada (2018–2019)
Formerly Director of Events (acting), Office of the Speaker of the House of Commons, Parliament of Canada (2018–2018)
Formerly Administrative Assistant, Office of the Speaker of the House of Commons, Parliament of Canada (2017–2018)
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Finance Canada (FIN), Fisheries and Oceans Canada (DFO), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Justice Canada (JC), National Defence (DND), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (23)Hide details
- Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
- Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
- Federal policies that relate to possible models of pharmacare
- Federal Buy Canadian Procurement Policy as it relates to government drug procurement practices and the implications for the biopharmaceutical industry
- Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
- Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
- National Strategy for Drugs for Rare Diseases
- World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
- World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry
- World Health Organization (WHO) issues concerning the biopharmaceutical industry
- Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
- Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
- Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
- Income Tax Act as it relates to biopharmaceutical products
- Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
- Free trade agreements as they relate to the biopharmaceutical industry
- Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
- Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
- Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
Registration 957857-371-135. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Bettina Hamelin (157), Pamela Fralick (85), David Renwick (37).
-
Reported by Bettina Hamelin · In-house (organization)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
- Niloo Boroun · Director of International Policy, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Eric Costen · Deputy Secretary to the Cabinet (Operations), Privy Council Office (PCO)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Kasondra White · Acting Director General, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
-
Reported by Bettina Hamelin · In-house (organization)
- Gord Johns · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Karim Bardeesy · Parliamentary Secretary to the Minister of Industry
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Raquel Dancho · Member of Parliament
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Philip Jennings · Deputy Minister of Innovation, Science and Economic Development Canada (ISED), Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
-
Reported by Bettina Hamelin · In-house (organization)
- Michael DeJong · Assistant Secretary, Regulatory Affairs Sector, Treasury Board Secretariat, Treasury Board Of Canada Secretariat (TBS)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Joss Reimer · Chief Public Health Officer, Public Health Agency of Canada (PHAC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
and 10 moreShow fewer
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Shalene Curtis-Micallef · Deputy Minister of Health, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
- Justine Frame · Senior Policy Advisor, Health Canada (HC)
- Fatoumata Bah · Policy Advisor, Health Canada (HC)
- Scott Lohnes · Senior Advisor, Health Canada (HC)
- Supriya Sharma · Chief Medical Advisor to the Deputy Minister and Senior Medical Advisor, Health Canada (HC)
- Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
- Shalene Curtis-Micallef · Deputy Minister of Health, Health Canada (HC)
and 6 moreShow fewer
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health, Health Canada (HC)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
- Justine Frame · Senior Policy Advisor, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
- Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Yash Nanda · Senior Policy Advisor, Prime Minister's Office, Prime Minister's Office (PMO)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Bettina Hamelin · In-house (organization)
- Tom Kmiec · Member of Parliament
Free trade agreements as they relate to the biopharmaceutical industry Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
-
Reported by Bettina Hamelin · In-house (organization)
- Sonia Sidhu · Member of Parliament
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Bettina Hamelin · In-house (organization)
- Dan Mazier · Member of Parliament
Free trade agreements as they relate to the biopharmaceutical industry Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
-
Reported by Bettina Hamelin · In-house (organization)
- Ali Ehsassi · Parliamentary Secretary to the President of the King’s Privy Council for Canada and Minister responsible for Canada–U.S. Trade, Privy Council Office (PCO)
Free trade agreements as they relate to the biopharmaceutical industry Read more
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
-
Reported by Bettina Hamelin · In-house (organization)
- Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
and 6 moreShow fewer
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
-
Reported by Bettina Hamelin · In-house (organization)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
and 3 moreShow fewer
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
-
Reported by Bettina Hamelin · In-house (organization)
- Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
and 6 moreShow fewer
- Annahat Kochar · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Celia Lourenco · Associate Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Sara O’Connor · Director General, Health Canada (HC)
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.